NCT04957615 2026-04-15
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
29 trialsNCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT07404332 2026-02-11
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Not yet recruiting
NCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT05219435 2025-09-24
VEXILLUM
Spanish Oncology Genito-Urinary Group
Phase 2 Active not recruiting
NCT02775292 2025-07-30
NYM
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03406871 2025-01-24
REGONIVO
National Cancer Center Hospital East
Phase 1 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT03525925 2024-03-18
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Unknown
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT05175235 2023-03-03
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Phase 1/2 Unknown
NCT03431948 2023-02-16
C4-MOSART
University of Chicago
Phase 1 Completed
NCT03453892 2023-02-16
ST-ICI
University of Erlangen-Nürnberg Medical School
Completed
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
NCT04761744 2021-02-21
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
Phase 2 Unknown
NCT04315155 2020-10-28
BENEFIT
University of Utah
Phase 1 Withdrawn
NCT04131621 2020-04-15
CheCUP
University Hospital Heidelberg
Phase 2 Unknown
NCT03864575 2019-07-12
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT03652233 2019-06-20
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT03792724 2019-01-03
INTRUST
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Unknown